ArticleThe Journal of hospital infection2021
Healthcare-associated infection impact with bioaerosol treatment and COVID-19 mitigation measures.
Article in The Journal of hospital infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Impact of COVID-19 Pandemic on Healthcare-Associated Infections: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2023Review
- Trending prevalence of healthcare-associated infections in a tertiary hospital in China during the COVID-19 pandemic.BMC infectious diseases · 2023Article
- Control technologies to prevent aerosol-based disease transmission in animal agriculture production settings: a review of established and emerging approaches.Frontiers in veterinary science · 2023Review
- Healthcare-associated infections in the context of the pandemic.Frontiers in health services · 2023Article
- Undergraduates' Negative Emotion and Academic Procrastination During COVID-19: Life Autonomy as a Mediator and Sense of School Belonging as a Moderator.Psychology research and behavior management · 2023Article
- A Blockchain-Based Life-Cycle Environmental Management Framework for Hospitals in the COVID-19 Context.Engineering (Beijing, China) · 2023Article
- Role of bioaerosol in virus transmission and material-based countermeasures.Exploration (Beijing, China) · 2022Review
- Direct and indirect healthcare and carbon savings with ACTIVE Particle ControlFrontiers in public health · 2022Article
- COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education.TheScientificWorldJournal · 2022Review
- Elevator Cabin Decontamination With ACTIVE Particle Control™ Technology.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe real-world impact of breathing zone air purification and coronavirus disease 2019 (COVID-19) mitigation measures on healthcare-associated infections is not well documented. Engineering solutions to treat airborne transmission of disease may yield results in controlled test chambers or single rooms, but have not been reported on hospital-wide applications, and the impact of COVID-19 mitigation measures on healthcare-associated infection rates is unknown.
aimTo determine the impact of hospital-wide bioaerosol treatment and COVID-19 mitigation measures on clinical outcomes.
methodsThe impact of the step-wise addition of air disinfection technology and COVID-19 mitigation measures to standard multi-modal infection control on particle counts, viral and bacterial bioburden, and healthcare-associated infection rates was investigated in a 124-bed hospital (>100,000 patient-days over 30 months). FINDINGS AND
conclusionThe addition of air disinfection technology and COVID-19 mitigation measures reduced airborne ultrafine particles, altered hospital bioburden, and reduced healthcare-associated infections from 11.9 to 6.6 (per 1000 patient-days) and from 6.6 to 1.0 (per 1000 patient-days), respectively (P<0.0001, R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.